KALA BIO (KALA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
19 Dec, 2025Executive summary
The annual meeting is scheduled for January 30, 2026, and will be held virtually to enhance shareholder participation globally.
Shareholders of record as of December 30, 2025, are eligible to vote on key proposals, including director elections, executive compensation, auditor ratification, share issuances, amendments to the certificate of incorporation, and potential adjournment.
The board recommends voting in favor of all proposals, which are designed to support capital structure flexibility, compliance with Nasdaq requirements, and corporate governance best practices.
Voting matters and shareholder proposals
Seven proposals are up for vote: election of three Class II directors, advisory vote on executive compensation, ratification of HTL International, LLC as auditor, approval of share issuance upon preferred stock conversion, increase in authorized shares, reverse stock split, and adjournment if needed.
Approval of share issuance and increase in authorized shares are linked to recent financing and balance sheet restructuring, including a $6 million preferred equity investment and loan settlement.
Reverse stock split proposal allows the board to select a ratio between 1-for-2 and 1-for-100 to maintain Nasdaq listing and manage capital structure.
Shareholders may submit proposals for the 2026 annual meeting by specified deadlines and procedures.
Board of directors and corporate governance
The board consists of seven members divided into three classes with staggered three-year terms; independence is maintained per Nasdaq rules.
David Lazar serves as CEO, CFO, and Chair; Andrew Koven is Lead Independent Director.
Committees include audit, compensation, and nominating/governance, each with defined charters and independent membership.
The board held eight meetings in 2024, with all directors attending at least 75% of meetings.
Director nomination emphasizes integrity, business acumen, and diversity of skills and backgrounds.
Latest events from KALA BIO
- Registering 241M+ shares for resale amid Nasdaq compliance risks and leadership changes.KALA
Registration Filing10 Feb 2026 - KPI-012's phase II-B trial for PCED targets a major unmet need, with data expected Q1 2025.KALA
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference2 Feb 2026 - All proposals, including director elections and share increase, passed unanimously.KALA
AGM 20262 Feb 2026 - KPI-012 nears phase IIb readout for PCED, targeting broad unmet needs in rare eye diseases.KALA
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - David Lazar's executive experience highlighted as board nomination is updated for the 2025 meeting.KALA
Proxy Filing26 Jan 2026 - Phase IIb trial for a novel secretome therapy in PCED targets broad approval and billion-dollar market.KALA
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Settlements with Baker Bros. and LifeSci increased outstanding shares to 27.8 million.KALA
Proxy Filing6 Jan 2026 - Proxy seeks approval for director elections, share issuance, capital changes, and auditor ratification.KALA
Proxy Filing30 Dec 2025 - Late-stage trial for a stem cell-based eye drop targets broad PCED market with imminent data.KALA
H.C. Wainwright 27th Annual Global Investment Conference27 Dec 2025